|
|
|
|
Vtv Therapeutics Inc (NASDAQ: VTVT) |
|
Price: $19.0000
$-0.36 
-1.860%
|
| Day's High:
| $19.48
| Week Perf:
| 2.54 %
|
| Day's Low: |
$ 18.15 |
30 Day Perf: |
-16.45 % |
| Volume (M): |
7 |
52 Wk High: |
$ 29.19 |
| Volume (M$): |
$ 121 |
52 Wk Avg: |
$17.55 |
| Open: |
$18.99 |
52 Wk Low: |
$12.12 |
|
|
| Market Capitalization (Millions $) |
110 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
57 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-23 |
| Cash Flow (TTM) (Millions $) |
27 |
| Capital Exp. (TTM) (Millions $) |
0 |
Vtv Therapeutics Inc
Vtv Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs to treat various diseases. The company is known for its expertise in target-based drug discovery and employs a unique approach to drug development, utilizing cutting-edge technologies and collaborative research partnerships. Vtv Therapeutics aims to bring novel therapeutics to the market that can significantly improve patient outcomes and address unmet medical needs.
Company Address: 3980 Premier Dr High Point 27265 NC
Company Phone Number: 841-0300 Stock Exchange / Ticker: NASDAQ VTVT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Fri, Mar 21 2025 7:47 PM UTC
Abstract: vTv Therapeutics, a clinical-stage pharmaceutical company, has released its financial results for the fourth quarter and full year of 2024. The announcement highlights strategic corporate advancements alongside significant clinical developments, including the lifting of a clinical hold for their late-stage cadisegliatin program for diabetes. This article examines...
|
| Clinical Study
Published Fri, Jul 26 2024 8:05 PM UTC
vTv Therapeutics Inc. Faces Setback in Promising Diabetes Research HIGH POINT, N.C., July 26, 2024 vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company renowned for its innovative clinical portfolio of small molecules and a lead program targeting diabetes, today announced a significant development. The United States Food and Drug Administration (FDA...
|
| Vtv Therapeutics Inc
/>vTv Therapeutics Inc., a leading clinical stage biopharmaceutical company, recently announced significant advancements in its mission to develop revolutionary treatments for type 1 diabetes (T1D). The company is focused on introducing an adjunctive therapy to insulin, aiming to improve the lives of millions of T1D patients. Alongside its recent financial results, vTv Therapeutics' stock performance reflects investors' positive sentiment towards its innovative approach.
Recent Developments:
vTv Therapeutics Inc. has submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial is specifically designed to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adjunctive therapy to insulin for the treatment of T1D in adults. T1D is a chronic autoimmune disease characterized by the body's inability to produce insulin, resulting in high blood sugar levels. Currently, insulin therapy is the standard treatment for T1D. However, vTv Therapeutics aims to revolutionize the field by introducing an innovative adjunctive therapy.
|
| Vtv Therapeutics Inc
Vtv Therapeutics Inc is a clinical stage biopharmaceutical company that is focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The company recently reported its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
In terms of financial performance, for the fiscal period ending December 31, 2023, VTVT decreased its loss per share to $-1.54 per share, compared to $-1.88 per share in the previous year. Earnings per share also improved from $-3.20 per share to $-1.54 per share. The revenue remained unchanged at $0.00 million, compared to $0.01 million in the same reporting period a year prior. The company reported a net shortfall of $-4.441 million, an improvement from a deficit of $-6.090 million in the previous year. The net loss for the fiscal year was $-25.97 million, with revenue for the 12 months totaling $0.00 million.
Vtv Therapeutics Inc has also made significant advancements in its clinical trials. The company recently submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial aims to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D) in adults. T1D is a chronic autoimmune disease characterized by the body's inability to produce insulin, resulting in high blood sugar levels. Insulin therapy is currently the standard treatment for T1D; however, vTv Therapeutics is striving to revolutionize the field by introducing an innovative adjunctive therapy that could potentially improve the lives of millions of patients.
In terms of stock performance, Vtv Therapeutics Inc shares have recorded a solid gain of 9.32% over the past 7 days and are up by 39.07% in 2024. However, the shares are currently trading on the NASDAQ at -29.9% below its 52-week average.
|
| Product Service News
Published Mon, Mar 4 2024 1:01 PM UTC
vTv Therapeutics Inc., a renowned clinical stage biopharmaceutical company with a focus on the development of innovative treatments, has recently submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial aims to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adj...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.21 $ |
| Revenues (TTM) |
0.18 $
|
| Cash Flow (TTM) |
4.73 $ |
| Cash |
6.38 $
|
| Book Value |
2.48 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.21 $
|
| Revenues (TTM) |
0.18 $ |
| Cash Flow (TTM) |
4.73 $ |
| Cash |
6.38 $
|
| Book Value |
2.48 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
4.04%